about
Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic propertiesEffect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders.Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis.Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro.Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials.Methodologic issues in clinical trials for prevention or risk reduction in osteoarthritisOARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group.Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and FrailtyA randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritisPharmacokinetic profile of dexloxiglumide.Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular).Experimental pharmacology of glucosamine sulfate.Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study.Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate.The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study.Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.Development and validation of two liquid chromatography-tandem mass spectrometry methods for the determination of silibinin and silibinin hemisuccinate in human plasma.Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro.In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate.Development and validation of a HPLC-ES-MS/MS method for the determination of glucosamine in human synovial fluid.Influence of transdermal estradiol in the regulation of leptin levels of postmenopausal women: a double-blind, placebo-controlled study.Radiologic features poorly predict clinical outcomes in knee osteoarthritis.Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency.Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis.The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endEvaluation of Levothyroxine Bioavailability after Oral Administration of a Fixed Combination of Soy Isoflavones in Post-menopausal Female Volunteers.Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.Glucosamine sulfate in osteoarthritis of the knee.Design and conduct of clinical trials in patients with osteoarthritis of the hand: recommendations from a task force of the Osteoarthritis Research Society International.Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasmaType 2 diabetes mellitus and osteoarthritisCorrect regimen of fluoride and calcium reduces the risk of vertebral fractures in postmenopausal osteoporosisEffects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humansClinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and MazzucaProopiomelanocortin, Preproenkephalin-A and Preprocholecystokinin mRNA in the Hypothalamus of CCI-Treated RatsEvaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mgEfficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial)Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period
P50
Q24630640-5441B240-1488-4B9F-8CAB-865BCC7BB1CAQ33466223-E34480A1-4D05-4D11-BEBD-CCE4C9B72B68Q33650279-32E82A31-7519-42B5-B40D-A7B6F0580D21Q34503637-A885B566-1383-4D56-A520-E300A2029D56Q34581685-A6C53173-7F3D-4106-A536-3C59B0E1005AQ35678484-D5E67FF2-1FA3-4944-AD69-403BB81D5D97Q35678507-2852AF93-DBFC-4688-9924-1B803F8B6067Q35894623-963B018D-2763-4BB1-91B3-E5A6EB7A9C51Q36148655-3CF14B1E-03DC-4D85-BC2D-7991DE748309Q36656408-5759E153-B0D3-4305-B26B-0B5D36F6733BQ38132963-8FAEDFB2-7EC1-4C04-B212-47191A2C0397Q38556244-35EFD1F7-92AF-4BAB-ACD4-823A7CC74897Q38684643-CEF1A315-C780-4849-A49E-065E5830E9AFQ40246877-EDBAD18B-AD29-44FE-8D23-C80BEF23A377Q40613208-FE54782C-6917-454A-851E-95E476A78619Q40953957-3AF6258A-614E-4356-BF11-D4BC25164B20Q42228718-759AF27B-9F8A-412D-AEB5-4889523F8F94Q42250371-D5B053F7-5F3A-4B30-BDF8-7FDEEC15FA24Q43090795-5C1C3FAC-E309-4D19-A839-84C6B4013A9DQ43090797-BEF86453-3316-448C-BBB7-0A3DCD8AF53CQ43300958-99469480-9467-4255-B407-3E612E95D03FQ43854534-C3C3B190-4F99-42D5-A194-03480C3CFBF5Q43939087-F963C078-1F90-441F-A733-400C90E28C58Q44860192-1E6794B0-A337-48A8-A2E9-6CFF16637E54Q45239805-D874D0B3-3B74-4530-974F-3718BD4F35C2Q46077162-08F020DB-142B-4504-BCF2-234F63FC7ED7Q46212849-C9C02694-6465-468F-942B-6C7B946346F8Q51011024-C257C13B-F5AE-4FEF-B566-63A4A9CFFC52Q52680975-F16512D1-E4DC-4DDB-A637-0761B8737E4EQ53017997-40201684-C2D3-4FF6-8B1B-2F2C4F8EDE40Q53255548-A5CD1C42-3EBC-4281-BAAC-9A71CBCD451EQ56996842-2F090B7B-EADA-480E-AA01-E8D7C03E6C93Q63352658-B78A6A99-A0FE-41AD-AE8F-888ACDEF0FEFQ74630055-82EDB677-CCFD-4129-A870-F7584D1A74E5Q74639045-BBBE9A29-FD30-43FC-8A96-BCA578734E45Q79795049-1367BAF8-CAA1-459C-AF63-A0AAA5BDB9B8Q83330634-20DCCC1A-D4B6-4722-8B70-C4744CD24DE2Q83737933-4CD1E604-2C2F-42B2-BE8D-8DBC320D2467Q87059694-EE7677B8-39B7-4BD5-884E-45CEFD0F666EQ87439606-F84C6149-98A6-4BFB-AB25-18425350987D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lucio C Rovati
@ast
Lucio C Rovati
@en
Lucio C Rovati
@es
Lucio C Rovati
@nl
type
label
Lucio C Rovati
@ast
Lucio C Rovati
@en
Lucio C Rovati
@es
Lucio C Rovati
@nl
prefLabel
Lucio C Rovati
@ast
Lucio C Rovati
@en
Lucio C Rovati
@es
Lucio C Rovati
@nl
P106
P1153
35429590100
P21
P31
P496
0000-0002-3425-1583